First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery...

Related Keywords

Vilaseca ,Comunidad Autonoma De Cataluna ,Spain ,Madrid ,Belgium ,Beerse ,Region Flamande ,Barcelona ,Indianj Urol ,Janssen Cilag Gmb ,Janssen Pharmaceutica ,Jeffrey Infante ,Martin Vogel ,Urology Care Foundation ,Janssen Research Development ,None Of The Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,European Society For Medical Oncology ,Astex Therapeutics ,Oncology Early Clinical Development ,Translational Research ,Astex Announces New Drug Discovery Alliance ,Janssen Pharmaceutical Companies ,Johnson ,Exchange Commission ,Companies Of Johnson ,Late Breaking Mini Oral Presentation Session ,European Society ,Medical Oncology ,Area Lead Oncology ,Bacillus Calmette Gu ,Global Head ,Janssen Research ,Astex Therapeutics Limited ,Pharmaceutical Companies ,Pulmonary Hypertension ,Janssen Cilag Gmbh ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Efficacy Results ,Intravesical Delivery System ,Muscle Invasive Bladder Cancer ,With Select ,Erdafitinib Intravesical Delivery System ,Localized Bladder ,Erdafitinib Versus Investigator Choice ,Participants Who Received Bacillus Calmette Gu ,Participants With Metastatic ,Locally Advanced Urothelial ,Participants With Advanced Solid Tumors ,Fibroblast Growth Factor Receptor ,Gene Alterations ,Erdafitinib Compared With Vinflunine ,Participants With Advanced Urothelial Cancer ,Selected Fibroblast Growth Factor Receptor ,Gene Aberrations ,Non Muscle Invasive Bladder ,Janssen Emea ,